| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Lightcap Jeffrey C | Director | C/O HEARTFLOW, INC., 331 E. EVELYN AVENUE, MOUNTAIN VIEW | /s/ Angela Ahmad, Attorney-in-Fact for Jeffrey C. Lightcap | 2025-08-07 | 0001519465 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | HTFL | Series C Preferred Stock | Aug 7, 2025 | Common Stock | 624K | By HealthCor Partners Fund II, L.P. | F1, F2 | |||||||
| holding | HTFL | Series C Preferred Stock | Aug 7, 2025 | Common Stock | 1.25M | By HealthCor Partners Fund, L.P. | F1, F2 | |||||||
| holding | HTFL | Series D Preferred Stock | Aug 7, 2025 | Common Stock | 1.63M | By HCPCIV 1, LLC | F2, F3 | |||||||
| holding | HTFL | Series D Preferred Stock | Aug 7, 2025 | Common Stock | 209K | By HealthCor Partners Fund II, L.P. | F2, F3 | |||||||
| holding | HTFL | Series E Preferred Stock | Aug 7, 2025 | Common Stock | 1.1M | By HCPCIV 1, LLC | F2, F4 | |||||||
| holding | HTFL | Series F Preferred Stock | Aug 7, 2025 | Common Stock | 1.34M | By HCPCIV 1, LLC | F2, F5 | |||||||
| holding | HTFL | Series F-1 Preferred Stock | Aug 7, 2025 | Common Stock | 453K | By HCPCIV 1, LLC | F2, F5 | |||||||
| holding | HTFL | Convertible Promissory Note | Aug 7, 2025 | Common Stock | $1.46M | By HCPCIV 1, LLC | F2, F6 |
| Id | Content |
|---|---|
| F1 | Each share of Series C preferred stock is convertible on a 1-to-0.5764 basis into shares of Heartflow, Inc.'s ("Heartflow") common stock and has no expiration date. The Series C preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1-for-2.92 reverse stock split of Heartflow common stock, which became effective on July 31, 2025. |
| F2 | Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| F3 | Each share of Series D preferred stock is convertible on a 1-to-0.6467 basis into shares of Heartflow's common stock and has no expiration date. The Series D preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1-for-2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025. |
| F4 | Each share of Series E preferred stock is convertible on a 1-to-0.6951 basis into shares of Heartflow's common stock and has no expiration date. The Series E preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1-for-2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025. |
| F5 | Each share of Series F preferred stock and Series F-1 preferred stock is convertible on a 1-to-0.3425 basis into shares of Heartflow's common stock and has no expiration date. The Series F preferred stock and Series F-1 preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1-for-2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025. |
| F6 | Represents the outstanding principal amount of a convertible promissory note held by HCPCIV 1, LLC, which will automatically convert upon consummation of Heartflow's initial public offering into shares of common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. These shares of common stock issuable upon conversion of the convertible promissory note have no expiration date. |
Remarks: Exhibit 24 - Power of Attorney.